Cochlear implants for children and adults with severe to profound deafness (TA566)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2019
Dinutuximab beta for treating neuroblastoma (TA538)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2018
Immunosuppressive therapy for kidney transplant in children and young people (TA482)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 July 2017
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2013
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2011
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 January 2011
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2010
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2007
Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2002
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 August 2000
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC